Tag: M.W:200-300

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.169447-70-5,(S)-tert-Butyl 2-methylpiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

A mixture of the product of step A (500 mg, 2.5 mmol), methyl 4-(bromomethyl)-3- (trifluoromethyl)benzoate (891 mg, 3.0 mmol) and Et3N(505 mg, 5.0 mmol) in DCM (20 mL) was stirred at room temperature for 2 hours. The reaction mixture was diluted with DCM (lOOmL), washed with brine (30 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (silica weight: 10 g, eluted with petroleum ether/EA: 10/1) to give the title compound (700 mg, 70%) as oil. 1H MR (400 MHz, CDC13) delta 8.31 (s, 1H), 8.19 (d, J= 8.0 Hz, 1H), 7.95 (d, J= 8.0 Hz, 1H), 4.26-4.16 (m, 1H), 3.95 (s, 3H), 3.86-3.80 (m, 1H), 3.66 (s, 2H), 3.18 – 3.07 (m, 1H), 2.76- 2.68 (m, 1H), 2.58-2.51 (m, 1H), 2.30-2.23 (m, 1H), 2.18 – 2.08 (m, 1H), 1.46 (s, 9H), 1.28- 1.25 (m, 3H)ppm.

169447-70-5, The synthetic route of 169447-70-5 has been constantly updated, and we look forward to future research findings.

Reference：
Patent; BEIGENE, LTD.; ZHOU, Changyou; ZHANG, Guoliang; WO2014/206344; (2014); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.163765-44-4,(R)-1-Boc-3-Methylpiperazine,as a common compound, the synthetic route is as follows.

A 100-mL round-bottom flask was charged with triphosgene (0.743 g, 2.50 mmol, 0.50 equiv), tert-butyl (R)-3-methylpiperazine-1-carboxylate (1.00 g, 5.00 mmol, 1.00 equiv), and dichloromethane (10 mL). DIPEA (1.94 g, 15.0 mmol, 3.00 equiv) was added at 0 C. The reaction was stirred for 3 hours at room temperature and quenched with water (80 mL). The mixture was extracted with dichloromethane (2*100 mL) and the organic layers were combined, washed with brine (2*80 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to provide 1.40 g of tert-butyl (R)-4-(chlorocarbonyl)-3-methylpiperazine-1-carboxylate as a yellow oil. LCMS (ESI, m/z): 263 [M+H]+.

163765-44-4, 163765-44-4 (R)-1-Boc-3-Methylpiperazine 2756811, apiperazines compound, is more and more widely used in various fields.

Reference：
Patent; ABIDE THERAPEUTICS, INC.; GRICE, Cheryl A.; CISAR, Justin S.; DUNCAN, Katharine K.; FENG, Yu; WIENER, John J.M.; WEBER, Olivia D.; (79 pag.)US2018/256566; (2018); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

259808-67-8, 1-Boc-3,3-Dimethylpiperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A vial was charged with 5-amino-3,6-dichloro-l,2,4-triazine (736 mg, 4.46 mmol), diisopropylethylamine (2.0 mL, 11.48 mmol), tert-butyl 2-(3,3-dimethylpiperazin-l- yl)acetate (1.0875 g, 4.52 mmol) in dioxane (8 mL). The mixture was heated at 155 C for 12 h using microwave. The mixture was concentrated to remove all of solvent. The residue was treated with saturated sodium bicarbonate solution, extracted with dichloromethane (4 x 50 mL). The combined organic solution was washed with brine, dried over anhydrous sodium sulfate, concentrated. The residue was separated with flash column chromatography on silica gel using 1-10% methanol in dichloromethane, and 30-100% ethyl acetate/Hexane to afford product (201.8 mg) in 13% yield. NMR (500 MHz, Chloroform-*/) delta 5.12 (s, 2H), 4.06 – 4.02 (m , 2H), 3.52 – 3.46 (m, 2H), 1.50 (s, 6H), 1.44 (s, 9H). MS for C 14H23CIN6O2: 343.2 (MH+).

259808-67-8, As the paragraph descriping shows that 259808-67-8 is playing an increasingly important role.

Reference：
Patent; NEKTAR THERAPEUTICS (INDIA) PVT. LTD.; NEKTAR THERAPEUTICS; SHARMA, PANKAJ; KHATRI, VIJAY KUMAR; GU, XUYUAN; SONG, YUAN; SHEN, MICHAEL LIXIN; SAUTHIER, JENNIFER RIGGS; ANAND, NEEL K.; KOZLOWSKI, ANTONI; ODINECS, ALEKSANDRS; RILEY, TIMOTHY A.; REN, ZHONGXU; MU. YONGQI; SHEN, XIAOMING; YUAN. XUEJUN; AURRECOECHEA, NATALIA; O’MAHONY, DONOGH JOHN ROGER; WO2015/92819; (2015); A2;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.300543-56-0,(R)-1-((4-Chlorophenyl)(phenyl)methyl)piperazine,as a common compound, the synthetic route is as follows.

General procedure: The title compound was prepared according to General Protocol B. NMR (400 MHz, DMSO-c delta 7.48 – 7.14 (m, 9H), 4.29 (s, 1 H), 2.38 (s, 4H), 2.34 – 2.20 (m, 6H); LCMS ti (Method 1) = 4.630 min, m/z 317.2 [M+H+].General Protocol B. A solution of amine (0.105 mmol) in MeOH (1.00 mL) was treated at room temperature with aldehyde (0.525 mmol to 1.05 mmol, 5.0 to 10.0 equiv.), NaCNBH4 (19.7 mg, 0.315 mmol, 3.0 equiv.) and acetic acid (0.018 mL, 0.315 mmol, 3.0 mmol). The reaction mixture was stirred at room temperature for 1 – 8 h and quenched with 1 N NaOH solution. The mixture was dried by blowing air, re-dissolved in DMSO, filtered and purified by HPLC. The title compound was prepared according to General Protocol B as a TFA salt. LCMS t, (Method 1) = 3.990 min, m/z 445.2 [M+H+]., 300543-56-0

As the paragraph descriping shows that 300543-56-0 is playing an increasingly important role.

Reference：
Patent; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; LIANG, Tsanyang Jake; FERRER, Marc; HE, Shanshan; HU, Xin; HU, Zongyi; MARUGAN, Juan Jose; SOUTHALL, Noel Terrence; XIAO, Jingbo; ZHENG, Wei; WO2015/80949; (2015); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.30459-17-7,1-(4-Trifluoromethylphenyl)piperazine,as a common compound, the synthetic route is as follows.

To a solution of 0.32 mmol 5-cyano-2-isopropylsulfanyl-benzoic acid in 5 ml tetrahydrofuran were added successively 0.31 mmol TBTU, 0.84 mmol N-ethyldiisopropylamine and 0.22 mmol 1-(4-trifluoromethylphenyl)-piperazine (commercially available, e.g. from Fluorochem). The reaction mixture was stirred at 35 C. for 16 h and then concentrated in vacuo. Chromatography (SiO2, ethyl acetate/heptane) followed by trituration in pentane afforded the title compound as an off-white solid (yield 94%). MS (m/e): 434.4 (M+H+, 100%)., 30459-17-7

As the paragraph descriping shows that 30459-17-7 is playing an increasingly important role.

Reference：
Patent; Jolidon, Synese; Narquizian, Robert; Norcross, Roger David; Pinard, Emmanuel; US2006/149062; (2006); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

187669-60-9, 1-(4-(Methylsulfonyl)phenyl)piperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 67; 4-{2-[4-(4-Methanesulfonylphenyl)piperazin-l-yl]acetyl}piperidine-l- carboxylic acid tert-butyl ester; To a solution of l-(4-methanesulfonylphenyl)piperazine (0.055g, 0.23mmol) in MeCN (2mL) was added 4-(2-bromoacetyl)piperidine-l-carboxylic acid tert-butyl ester (0.07g, 0.23mmol) and K2CO3 (0.035g, 0.25mmol). The mixture was heated at reflux for 4h then allowed to cool. EtOAc (2OmL) was added and the organic phase washed with water, brine, dried (MgSO4) and the solvent removed in vacuo. The crude mixture was purified by flash chromatography with EtOAc as eluent to afford the title compound (0.07g, 65%): RT = 2.45 min; m/z (ES+) = 466.4 [M+ H]+

187669-60-9, As the paragraph descriping shows that 187669-60-9 is playing an increasingly important role.

Reference：
Patent; PROSIDION LIMITED; WO2007/3964; (2007); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

115619-01-7, 4-(4-Ethylpiperazin-1-yl)phenylamine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: 1 equiv of piperazinyl amine was dissolved in pyridine (20 ml/g)and stirred at 0 C under inert atmosphere. 1.2 equiv of cinnamoylchloride derivative was dissolved in dry DCM (10 ml/g) and addeddropwise to above stirred solution at 0 C. The reaction mixturewasstirred for 3 h and was monitored by TLC. After completion of thereaction, the reaction mixturewas diluted withwater (20 ml/g) andethyl acetate (30 ml/g) followed by 2 N HCl to make it acidic. Theprecipitate came out which was filtered as yellow solid and furtherwashed with 2 N HCl and then water. The precipitate was suspendedin saturated bicarbonate solution and stirred vigorously toremove acid impurities. The crude compound was purified eitherby column chromatography or by recrystallization from ethyl acetateand hexane., 115619-01-7

As the paragraph descriping shows that 115619-01-7 is playing an increasingly important role.

Reference：
Article; Patel, Kavitkumar N.; Telvekar, Vikas N.; European Journal of Medicinal Chemistry; vol. 75; (2014); p. 43 – 56;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

129799-08-2, 1-tert-Butyl 3-methyl piperazine-1,3-dicarboxylate is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

1-tert-Butyl 3-methyl piperazine-1,3-dicarboxylate (1.5 g) was dissolved in DMF (50 mL). Potassium carbonate (1.7 g) and N-(4-chloromethyl-3-methyl-1,3-thiazol-2(3H)-ylidene)-N-methylamine hydrochloride (1.4 g) were added thereto, and the mixture was mixed at 80C overnight. The solvent was distilled off, the residue was poured into water, extracted with a mixed solution of chloroform-methanol, and the extract was dried over anhydrous magnesium sulfate. The solvent was distilled off to give tert-butyl 4-(((2Z)-3-methyl-2-(methylimino)-2,3-dihydro-1,3-thiazol-4-yl)methyl)-3-oxopiperazine-1-carboxylate (1.2 g) as a pale brown oily matter. The resulting oily matter was dissolved in trifluoroacetic acid (10 mL) and mixed at room temperature for 1 hour. The mixture was dissolved in dichloromethane (50 mL), and triethylamine (0.87 mL) was added thereto. With ice cooling, 3-((6-chloro-2-naphthyl)sulfonyl)propionic acid (0.97 g), HOBt (0.53 g) and WSC (0.65 g) were added thereto, and the mixture was mixed at room temperature for 16 hours. The reaction solution was basified with an aqueous potassium carbonate solution, then extracted with chloroform, and the extract was dried over anhydrous magnesium sulfate. The solvent was distilled off, and the residue was purified with a basic silica gel column to give the title compound (1.8 g) as a white powder. NMR (CDCl3) delta: 2.38-2.52 (1H, m), 2.83-2.91 (3.7H, m), 2.94 (3H, s), 3.23-3.40 (3.7H, m), 3.29 (3H, s), 3.48-3.66 (6.3H, m), 4.06-4.29 (1H, m), 4.77-4.96 (0.3H, m), 5.71 (0.3H, s), 7.73 (0.7H, s), 7.49-7.55 (1H, m), 7.88-7.94 (4H, m), 8.43 (1H, m)., 129799-08-2

The synthetic route of 129799-08-2 has been constantly updated, and we look forward to future research findings.

Reference：
Patent; Takeda Pharmaceutical Company Limited; EP1669352; (2006); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.216144-45-5,4-(4-Methylpiperazin-1-yl)benzylamine,as a common compound, the synthetic route is as follows.

Example 103 6-chloro-N-[4-(dimethylphosphoryl)phenyl]-N?-[4-(4-methylpiperazin-1-yl)benzyl]-1,3,5-triazine-2,4-diamine (0712) (0713) To a solution of 4,6-dichloro-N-[4-(dimethylphosphoryl)phenyl]-1,3,5-triazin-2-amine (prepared as in Example 102: 0.12 mmol) in 2 mL of ethanol is added 50 muL of triethylamine and 4-(4-methylpiperazine)-benzylamine (24 mg, 0.12 mmol). The mixture is microwaved at 120 degrees until formation of the desired compound. The reaction mixture is filtered through a syringe filter and purified by prep-HPLC., 216144-45-5

The synthetic route of 216144-45-5 has been constantly updated, and we look forward to future research findings.

Reference：
Patent; ARIAD PHARMACEUTICALS, INC.; Wang, Yihan; Huang, Wei-Sheng; Liu, Shuangying; Shakespeare, William C.; Thomas, Ranny M.; Qi, Jiwei; Li, Feng; Zhu, Xiaotian; Kohlmann, Anna; Dalgarno, David C.; Romero, Jan Antoinette C.; Zou, Dong; US2015/225436; (2015); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.960283-58-3,(S)-tert-Butyl 2-methylpiperazine-1-carboxylate hydrochloride,as a common compound, the synthetic route is as follows.

Description 79; 1 ,1 -Dimethylethyl (2S)-4-{[4-(acetylamino)-2-methylphenyl]methyl}-2-methyl-1 – piperazinecarboxylate (D79); lambda/-(4-Formyl-3-methylphenyl)acetamide (D78) (326 mg, 1.8 mmol), 1 ,1 -dimethylethyl (2S)-2-methyl-1 -piperazinecarboxylate hydrochloride (436 mg, 1.8 mmol), triethylamine (0.282 mL, 2 mmol) and sodium tri(acetoxy)borohydride (781 mg, 3.7 mmol) were stirred together in DCE (15 mL) for 17 h. Saturated aqueous NaHCO3 (15 mL) was added and the reaction mixture stirred for 1 h. The organic layer was separated and washed with water and brine, then dried and concentrated to give the crude product which was purified by chromatography. Elution with 0-100% ethyl acetate/petroleum ether yielded the title compound as a colourless oil (573 mg). deltaH (CDCI3, 400MHz) 7.27 (2H, m), 7.16 (1 H, d), 7.11 (1 H, br.s), 4.17 (1 H, m), 3.78 (1 H, m), 3.36 (2H, s), 3.02 (1H, m), 2.70 (1H, m), 2.56 (1 H, m), 2.36 (3H, s), 2.17 (4H, m), 1.95 (1 H, m), 1.45 (9H, s), 1.18 (3H, d). MS (ES): MH+ 362.3., 960283-58-3

As the paragraph descriping shows that 960283-58-3 is playing an increasingly important role.

Reference：
Patent; GLAXO GROUP LIMITED; WO2008/729; (2008); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics